Competitive PressureABS-101 showed the strongest odds of demonstrating a best-in-class clinical profile, potentially generating significant peak sales despite fierce competition in IBD.
Revenue ShortfallAbsci reported 1Q25 revenues of $1.2M, which fell short of the consensus estimate of $2.6M.
Risk FactorsRisks to the Buy rating include potential issues with partnerships, technology, clinical and regulatory challenges, and competition.